SARS 3CL Protease Antibody - 100 µg

Within the last two decades, SARS and MERS coronaviruses emerged as global health concerns causing severe acute respiratory syndromes. In December 2019, a novel coronavirus (SARS-CoV-2) was identified in Wuhan, Hubei province in China. The SARS-CoV genome encodes several non-structural proteins that are essential for the life cycle of the virus. The viral 3-chymotrypsin-like cysteine protease (3CL-PRO) enzyme controls coronavirus replication. 3CL-PRO is a proven drug discovery target in the case of SARS-CoV and MERS-CoV. Since the genome sequence of SARS-CoV-2 is very similar to that of SARS-CoV, inhibition of 3CL-PRO activity represents a viable strategy at the basis of a COVID-19 therapy. The SARS 3CL-PRO Protein Antibody recognizes and binds to both SARS-CoV and SARS-CoV-2 3CL-PRO enzymes.